Brookline Capital Markets Maintains Their Buy Rating on Veru Inc (VERU)


Brookline Capital Markets analyst Kumaraguru Raja maintained a Buy rating on Veru Inc (VERU) on February 13 and set a price target of $10. The company’s shares closed on Friday at $1.33, close to its 52-week low of $1.20.

According to TipRanks.com, Raja is a 1-star analyst with an average return of -2.4% and a 46.8% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Acer Therapeutics Inc, and Cellectar Biosciences.

Veru Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.83, implying a 413.5% upside from current levels. In a report issued on February 13, Maxim Group also maintained a Buy rating on the stock with a $6 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.37 and a one-year low of $1.20. Currently, Veru Inc has an average volume of 100.4K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts